Connect with us
[the_ad id="89560"]

Addictions

Opioid seizures exploded by 3,000% in Ontario city after “safer supply” experiment

Published

8 minute read

A London police drug seizure in April included 9,298 Dilaudid eight milligram tablets.

By Matthew Hannick

Doctors and journalists wondering why local police failed to disclose concerning statistic to public sooner

Nigel Stuckey saved more lives during the last five years of his policing career than the previous three decades combined. “Every time you go back to the street, it has a different flavour,” said Stuckey, a former sergeant with the London Police Service (LPS) who retired in 2022. “As a frontline police officer, you are constantly going to overdoses in the city. I’ve administered Narcan to multiple people, and this is just something that never existed before.”

Stuckey first noticed a dramatic increase in overdoses and drug-related crimes occurring throughout his city – London, Ontario – in 2019. While the reasons behind this increase were initially unclear, recent data released by the LPS suggest that “safer supply” programs may be contributing to the problem.

Safer supply programs aim to save lives by providing drug users with pharmaceutical-grade alternatives to the untested street supply. That typically means distributing hydromorphone, a heroin-strength opioid, as an alternative to illicit fentanyl. However, addiction experts say the program is having the opposite effect, as many people who are enrolled in safer supply programs are illegally selling or trading their prescribed hydromorphone on the black market, a practice known as “diversion.”

Harm reduction advocates claim that safer supply diversion is not a significant issue, but according to an investigation into London Police Services (LPS) seizure data by journalist Adam Zivo, the number of hydromorphone tablets seized in London increased by 3,000 per cent after access to safer supply was greatly expanded in 2020.

In 2019, the LPS seized fewer than 1,000 hydromorphone tablets. This number jumped significantly in 2020 and continued to rise afterwards, reaching 30,000 tablet seizures last year – an unprecedented amount. The London police estimate that last year’s record will be met or exceeded by the end of 2024.

Doctors have said that this is only representative of a small fraction of what is actually out there, and that just 3-4 of these pills, if snorted, are enough to induce an overdose in a new user.

Some people are wondering why this data wasn’t released months, if not years, earlier.

Dr. Sharon Koivu, a London-based addiction physician, was among the first to recognize the harms of safer supply and has been warning the public about widespread diversion for years. Based on her clinical experiences, she believes that diverted safer supply hydromorphone is causing new addictions and falling into the hands of youth.

When Koivu tried to speak out against safer supply and call attention to diversion and an overall lack of program transparency, she was bullied and told that the suffering she was witnessing didn’t exist. This harassment was so severe that her mental health deteriorated and she worried about whether her career had been irreversibly damaged – yet the London police had quietly possessed data showing that she was right all along.

“It’s become an ideological thing,” she said. “People seem to have doubled down on the information they have. They don’t want to hear from someone who has information and concerns that don’t align with their, I’m going to say, ideology – because it’s not science.”

News of skyrocketing hydromorphone seizures might have remained hidden from the public had it not been for a major bust earlier this year.

Subscribe to our newsletter to get our latest news and analysis – or donate to our investigative journalism fund.

On April 12, the London police announced a drug seizure which included 9,298 hydromorphone eight-milligram tablets. When Zivo inquired into this seizure, he received no answers to his questions for almost two months. He says that he was “stonewalled” and that the police seemed unwilling to release key data until it became impossible for them not to.

Zivo found it particularly concerning that the 2019-2023 hydromorphone seizure data was not released earlier. “Journalists and addiction physicians have been trying to raise the alarm about this issue for years,” he said, “but have been called liars, grifters and fearmongers, despite the fact that data validating their concerns existed and was held by the London Police Service.”

Stuckey, who now works as a documentary filmmaker covering London’s homelessness, addiction and mental health crisis, had a similar experience when he queried the LPS about the 9,290 hydromorphone pills seized this April.

Despite multiple requests for information about a possible connection to safer supply, the police service did not get back to him. He expressed frustration at the police’s unresponsiveness and worried that a lack of government transparency is endangering both the general public and law enforcement officers.

“Members of the London Police Service are being put in harm’s way dealing with organized crime and firearms to take drugs off the street, which were provided by the federal government. It’s absolute lunacy that we are paying one branch of government to rid a problem that was created by another branch of government,” said Stuckey.

It would be deeply concerning if the LPS knowingly withheld data pertaining to safer supply diversion. Not only has the failure to publish such data hindered informed public debate and policy development, it has also compromised the safety of the very communities which police are tasked with protecting.

According to Zivo, safer supply programs have benefitted from the silence of powerful institutions like the LPS. He said that, as there seems to be significant institutional resistance to acknowledging the community harms of safer supply, then more attention and trust should be given to local grassroots-level addiction medicine practitioners “who are bravely testifying to what they are seeing in their clinics.”

However, Dr. Koivu thinks that “the tide is turning” and that more people are beginning to understand the harms of safer supply

“I think it’s unfortunate that this data wasn’t made available sooner, when it was relevant to the funding of these programs and the changes we’re seeing in the city. The police need to be accountable for that. I really don’t understand their rationale for not addressing this” she said. “They hung me out to dry while knowing that what I was saying was accurate. If the police are afraid to come forward, no wonder physicians are afraid to come forward, too.”

A guest post by
Matthew
Matthew Hanick is a journalist living in Toronto.

Addictions

The War on Commonsense Nicotine Regulation

Published on

From the Brownstone Institute

Roger Bate  Roger Bate 

Cigarettes kill nearly half a million Americans each year. Everyone knows it, including the Food and Drug Administration. Yet while the most lethal nicotine product remains on sale in every gas station, the FDA continues to block or delay far safer alternatives.

Nicotine pouches—small, smokeless packets tucked under the lip—deliver nicotine without burning tobacco. They eliminate the tar, carbon monoxide, and carcinogens that make cigarettes so deadly. The logic of harm reduction couldn’t be clearer: if smokers can get nicotine without smoke, millions of lives could be saved.

Sweden has already proven the point. Through widespread use of snus and nicotine pouches, the country has cut daily smoking to about 5 percent, the lowest rate in Europe. Lung-cancer deaths are less than half the continental average. This “Swedish Experience” shows that when adults are given safer options, they switch voluntarily—no prohibition required.

In the United States, however, the FDA’s tobacco division has turned this logic on its head. Since Congress gave it sweeping authority in 2009, the agency has demanded that every new product undergo a Premarket Tobacco Product Application, or PMTA, proving it is “appropriate for the protection of public health.” That sounds reasonable until you see how the process works.

Manufacturers must spend millions on speculative modeling about how their products might affect every segment of society—smokers, nonsmokers, youth, and future generations—before they can even reach the market. Unsurprisingly, almost all PMTAs have been denied or shelved. Reduced-risk products sit in limbo while Marlboros and Newports remain untouched.

Only this January did the agency relent slightly, authorizing 20 ZYN nicotine-pouch products made by Swedish Match, now owned by Philip Morris. The FDA admitted the obvious: “The data show that these specific products are appropriate for the protection of public health.” The toxic-chemical levels were far lower than in cigarettes, and adult smokers were more likely to switch than teens were to start.

The decision should have been a turning point. Instead, it exposed the double standard. Other pouch makers—especially smaller firms from Sweden and the US, such as NOAT—remain locked out of the legal market even when their products meet the same technical standards.

The FDA’s inaction has created a black market dominated by unregulated imports, many from China. According to my own research, roughly 85 percent of pouches now sold in convenience stores are technically illegal.

The agency claims that this heavy-handed approach protects kids. But youth pouch use in the US remains very low—about 1.5 percent of high-school students according to the latest National Youth Tobacco Survey—while nearly 30 million American adults still smoke. Denying safer products to millions of addicted adults because a tiny fraction of teens might experiment is the opposite of public-health logic.

There’s a better path. The FDA should base its decisions on science, not fear. If a product dramatically reduces exposure to harmful chemicals, meets strict packaging and marketing standards, and enforces Tobacco 21 age verification, it should be allowed on the market. Population-level effects can be monitored afterward through real-world data on switching and youth use. That’s how drug and vaccine regulation already works.

Sweden’s evidence shows the results of a pragmatic approach: a near-smoke-free society achieved through consumer choice, not coercion. The FDA’s own approval of ZYN proves that such products can meet its legal standard for protecting public health. The next step is consistency—apply the same rules to everyone.

Combustion, not nicotine, is the killer. Until the FDA acts on that simple truth, it will keep protecting the cigarette industry it was supposed to regulate.

Author

Roger Bate

Roger Bate is a Brownstone Fellow, Senior Fellow at the International Center for Law and Economics (Jan 2023-present), Board member of Africa Fighting Malaria (September 2000-present), and Fellow at the Institute of Economic Affairs (January 2000-present).

Continue Reading

Addictions

The Shaky Science Behind Harm Reduction and Pediatric Gender Medicine

Published on

By Adam Zivo

Both are shaped by radical LGBTQ activism and questionable evidence.

Over the past decade, North America embraced two disastrous public health movements: pediatric gender medicine and “harm reduction” for drug use. Though seemingly unrelated, these movements are actually ideological siblings. Both were profoundly shaped by extremist LGBTQ activism, and both have produced grievous harms by prioritizing ideology over high-quality scientific evidence.

While harm reductionists are known today for championing interventions that supposedly minimize the negative effects of drug consumption, their movement has always been connected to radical “queer” activism. This alliance began during the 1980s AIDS crisis, when some LGBTQ activists, hoping to reduce HIV infections, partnered with addicts and drug-reform advocates to run underground needle exchanges.

The Bureau is a reader-supported publication.

To receive new posts and support my work, consider becoming a free or paid subscriber.

In the early 2000s, after the North American AIDS epidemic was brought under control, many HIV organizations maintained their relevance (and funding) by pivoting to addiction issues. Despite having no background in addiction medicine, their experience with drug users in the context of infectious diseases helped them position themselves as domain experts.

These organizations tended to conceptualize addiction as an incurable infection—akin to AIDS or Hepatitis C—and as a permanent disability. They were heavily staffed by progressives who, influenced by radical theory, saw addicts as a persecuted minority group. According to them, drug use itself was not the real problem—only society’s “moralizing” norms.

These factors drove many HIV organizations to lobby aggressively for harm reduction at the expense of recovery-oriented care. Their efforts proved highly successful in Canada, where I am based, as HIV researchers were a driving force behind the implementation of supervised consumption sites and “safer supply” (free, government-supplied recreational drugs for addicts).

From the 2010s onward, the association between harm reductionism and queer radicalism only strengthened, thanks to the popularization of “intersectional” social justice activism that emphasized overlapping forms of societal oppression. Progressive advocates demanded that “marginalized” groups, including drug addicts and the LGBTQ community, show enthusiastic solidarity with one another.

These two activist camps sometimes worked on the same issues. For example, the gay community is struggling with a silent epidemic of “chemsex” (a dangerous combination of drugs and anonymous sex), which harm reductionists and queer theorists collaboratively whitewash as a “life-affirming cultural practice” that fosters “belonging.”

For the most part, though, the alliance has been characterized by shared tones and tactics—and bad epistemology. Both groups deploy politicized, low-quality research produced by ideologically driven activist-researchers. The “evidence-base” for pediatric gender medicine, for example, consists of a large number of methodologically weak studies. These often use small, non-representative samples to justify specious claims about positive outcomes. Similarly, harm reduction researchers regularly conduct semi-structured interviews with small groups of drug users. Ignoring obvious limitations, they treat this testimony as objective evidence that pro-drug policies work or are desirable.

Gender clinicians and harm reductionists are also averse to politically inconvenient data. Gender clinicians have failed to track  long-term patient outcomes for medically transitioned children. In some cases, they have shunned detransitioners and excluded them from their research. Harm reductionists have conspicuously ignored the input of former addicts, who generally oppose laissez-faire drug policies, and of non-addict community members who live near harm-reduction sites.

Both fields have inflated the benefits of their interventions while concealing grievous harms. Many vulnerable children, whose gender dysphoria otherwise might have resolved naturally, were chemically castrated and given unnecessary surgeries. In parallel, supervised consumption sites and “safer supply” entrenched addiction, normalized public drug use, flooded communities with opioids, and worsened public disorder—all without saving lives.

In both domains, some experts warned about poor research practices and unmeasured harms but were silenced by activists and ideologically captured institutions. In 2015, one of Canada’s leading sexologists, Kenneth Zucker, was fired from the gender clinic he had led for decades because he opposed automatically affirming young trans-identifying patients. Analogously, dozens of Canadian health-care professionals have told me that they feared publicly criticizing aspects of the harm-reduction movement. They thought doing so could invite activist harassment while jeopardizing their jobs and grants.

By bullying critics into silence, radical activists manufactured false consensus around their projects. The harm reductionists insist, against the evidence, that safer supply saves lives. Their idea of “evidence-based policymaking” amounts to giving addicts whatever they ask for. “The science is settled!” shout the supporters of pediatric gender medicine, though several systematic reviews proved it was not.

Both movements have faced a backlash in recent years. Jurisdictions throughout the world are, thankfully, curtailing irreversible medical procedures for gender-confused youth and shifting toward a psychotherapy-based “wait and see” approach. Drug decriminalization and safer supply are mostly dead in North America and have been increasingly disavowed by once-supportive political leaders.

Harm reductionists and queer activists are trying to salvage their broken experiments, occasionally by drawing explicit parallels between their twin movements. A 2025 paper published in the International Journal of Drug Policy, for example, asserts that “efforts to control, repress, and punish drug use and queer and trans existence are rising as right-wing extremism becomes increasingly mainstream.” As such, there is an urgent need to “cultivate shared solidarity and action . . . whether by attending protests, contacting elected officials, or vocally defending these groups in hostile spaces.”

How should critics respond? They should agree with their opponents that these two radical movements are linked—and emphasize that this is, in fact, a bad thing. Large swathes of the public understand that chemically and surgically altering vulnerable children is harmful, and that addicts shouldn’t be allowed to commandeer public spaces. Helping more people grasp why these phenomena arose concurrently could help consolidate public support for reform and facilitate a return to more restrained policies.

Adam Zivo is director of the Canadian Centre for Responsible Drug Policy.

[This article was originally published in City Journal, a public policy magazine and website published by the Manhattan Institute for Policy Research]

Subscribe to The Bureau.

For the full experience, please upgrade your subscription and support a public interest startup.

We break international stories and this requires elite expertise, time and legal costs.

Continue Reading

Trending

X